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We analyzed the levels of circulating tissue plasminogen acti-
vator (tPA) and plasminogen activator inhibitor (PAI)–1 in 
acute hantavirus cardiopulmonary syndrome (HCPS) and 
hemorrhagic fever with renal syndrome (HFRS). The levels of 
tPA commonly increased in both diseases, whereas PAI-1 corre-
lated with disease severity in HCPS but not in HFRS.
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Hantaviruses cause two diseases: hantavirus cardiopulmonary 
syndrome (HCPS) and hemorrhagic fever with renal syndrome 
(HFRS). The hallmark of both diseases is increased vascular 
permeability [1, 2]; however, the most affected organ generally 
varies from the lungs in HCPS to the kidneys in HFRS. The type 
of hantavirus disease is determined by the causative species. 
Andes (ANDV) and Sin Nombre (SNV) hantaviruses cause 
HCPS with mortality that can reach 40% in South and North 
America, respectively. Puumala hantavirus (PUUV) causes 
a mild HFRS, also called nephropathia epidemica (NE; mor-
tality ~0.1%), mainly in Northern Europe and Russia, whereas 
Dobrava (DOBV) and Hantaan (HTNV) viruses cause severe 
HFRS (mortality 1%–5%) in the Balkans and East Asia, respect-
ively [3].
Hantavirus infection activates intravascular coagulation path-
ways in the acute stage of HCPS and HFRS [4–6]. At the same 
time, however, PUUV has been suggested to cause enhanced 
fibrinolysis [5], that is, excessive solubilization of blood clots, 
which we recently showed to be characterized by elevated ac-
tivity of circulating tissue plasminogen activator (tPA), whereas 
its main physiological inhibitor, plasminogen activator in-
hibitor–1 (PAI-1), remains unaltered [7]. In this study, we 
assessed the levels of tPA and PAI-1 in HCPS and HFRS caused 
by ANDV and DOBV, respectively, to better understand the role 
hemostatic regulation in hantavirus pathogenesis in general.
METHODS
The study protocol was conducted in accordance with the eth-
ical standards laid down by the Declaration of Helsinki and was 
approved by the Ethical Committee in Research of ANLIS “Dr 
C.  Malbrán,” Slovenian National Medical Ethics Committee, 
and the Ethics Committee of the Tampere University Hospital 
for serologically confirmed ANDV, DOBV, and PUUV cases, 
respectively. The study cohort consisted of patient samples that 
were collected ≤10 days after the beginning of the disease, that 
is, after onset of fever. Severe HCPS was classified, for example, 
due to pulmonary failure and need of mechanical ventilation, 
whereas signs of lower respiratory compromise were considered 
mild HCPS. Non-HCPS cases with pulmonary complications 
were included as reference. The DOBV patients were classified 
as severe or mild, for example, based on the need for dialysis. 
Additional information on patient demographics and disease 
classification criteria can be found in Supplementary Table  1 
and the Supplementary Methods, respectively.
Protein levels of tPA and PAI-1 were quantitated from patient 
plasma or serum by enzyme-linked immunosorbent assays, 
similar to methods described previously [7].
RESULTS
The levels of circulating tPA were significantly elevated above 
control in both severe and mild acute HCPS but not in symp-
tomatic non-HCPS cases (Figure  1A). Furthermore, tPA was 
significantly increased in severe as compared with mild HCPS. 
Its main physiological inhibitor, PAI-1, was also found to be 
increased above control in severe HCPS. However, in contrast 
to tPA, PAI-1 was not elevated in the mild HCPS or non-HCPS 
groups (Figure  1B). Thus, simultaneously elevated circulating 
levels of tPA and PAI-1 distinguish severe HCPS from mild 
HCPS and symptomatic non-HCPS cases. Strikingly, when 
taking into account all HCPS cases in our cohort, a robust cor-
relation between fatality and PAI-1 (r = .514; P = .001), but not 
tPA (r = .262; P = .1), was observed.
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To get further insight into the upregulation kinetics and 
the role of tPA and PAI-1 in HCPS disease severity, we fur-
ther classified severe HCPS to fatal and nonfatal cases at 
early acute stage (≤5  days after onset of fever) (Figure  1C) 
and found either statistically significantly or close to signif-
icantly elevated levels of PAI-1 in fatal HCPS as compared 
with mild (P = .001) or severe but nonfatal (P = .073) cases, 
respectively. tPA levels did not differ between groups. These 
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Figure 1. Levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI)–1 in acute hantavirus cardiopulmonary syndrome (HCPS) and hemorrhagic 
fever with renal syndrome (HFRS). Box plots of the levels of tPA (A) and PAI-1 (B) in acute (≤10 days after onset of disease) serum samples of severe (n = 18) and mild (n = 22) 
Andes (ANDV)-caused HCPS, non-HCPS cases (n = 5 for tPA and n = 12 for PAI-1) with similar symptoms to HCPS, and healthy volunteers (n = 10) as controls. (C) The levels 
of tPA and PAI-1 in early acute (≤5 days after onset of disease) serum samples of fatal (n = 7), severe but nonfatal (n = 4), and mild (n = 15) ANDV-caused HCPS. The levels of 
tPA (D) and PAI-1 (E) in acute (≤10 days after onset of disease) plasma samples of Dobrava (DOBV)- (n = 7) and Puumala hantavirus (PUUV)–caused (n = 16) HFRS in addition 
to healthy volunteers (n = 15) as controls. (F) The levels of tPA and PAI-1 in acute plasma samples of mild (n = 4) and severe (n = 3) DOBV-caused HFRS. Box plots illustrate 
the median value (center horizontal line), interquartile range (the lower and upper quartiles), and the highest and lowest values (whiskers) that are not outliers. Distributions 
across groups were compared by the Mann-Whitney U test. **Statistically highly significant difference at P < .01. *Statistically significant difference at P < .05.
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findings suggest a direct role for PAI-1, but not tPA, in the 
fatality of HCPS.
The levels of tPA and PAI-1 were also compared in the 
plasma of acute DOBV- and PUUV-caused HFRS patients. 
As seen in Figure 1D, the median levels of tPA were increased 
significantly above control in HFRS irrespective of the causa-
tive virus, but were further elevated by DOBV as compared 
with PUUV. While PAI-1 was not elevated in PUUV-HFRS 
(Figure  1E), it was significantly increased above control in 
DOBV-HFRS. This finding suggests a marked difference in 
regulation of PAI-1 based on the etiology and/or severity of 
HFRS. Interestingly, however, when categorizing DOBV-HFRS 
to mild vs severe forms of the disease based mainly on the 
extent of kidney failure and need for hemodialysis, PAI-1 was 
significantly lower in severe DOBV-HFRS, whereas no change 
between groups was observed for tPA.
These results indicate marked differences between the severe 
forms of HCPS and HFRS in the regulation of PAI-1. Further 
corroborating this difference, tPA was found to strongly correl-
ate with PAI-1 in HCPS (r = .471; P = .002) but not in DOBV-
HFRS (r = .402; P = .371). No correlation was observed between 
tPA or PAI-1 with platelet counts in HCPS or patient age in 
HCPS or HFRS (data not shown).
DISCUSSION
The results of this study show for the first time that circu-
lating levels of tPA are increased in acute HCPS and HFRS 
caused by ANDV and DOBV, respectively. In addition, higher 
tPA levels were found in DOBV- vs PUUV-caused HFRS and 
in severe vs mild HCPS, indicating a possible role for tPA 
in hantavirus pathogenesis. This is in accordance with our 
previous study, where tPA was found to positively correlate 
with hemorrhages in PUUV-HFRS [7]. However, no signifi-
cant differences in tPA levels were observed between severe 
vs mild DOBV-HFRS or fatal vs nonfatal severe HCPS, indi-
cating that additional factors are necessary to fully explain 
virulence in both diseases.
In contrast to tPA, its main physiological inhibitor, PAI-1, 
was only increased in severe HCPS and generally in DOBV-
HFRS. Furthermore, PAI-1 levels were nearly statistically sig-
nificantly elevated in fatal vs nonfatal severe HCPS, indicating 
a possible role for this protein in the mortality of HCPS. This 
latter finding is in accordance with a previous report indicat-
ing higher plasma PAI-1 levels in fatal SNV-caused HCPS as 
compared with nonfatal cases [4]. However, seemingly contra-
dicting the possible role of PAI-1 in the pathogenesis of HFRS, 
it was reduced in severe vs mild DOBV-HFRS (Figure 1F) and 
not elevated at all in PUUV-HFRS (Figure 1E) [7].
Due to differences in blood sampling (serum vs plasma), we 
were not capable of reliably comparing the quantity of PAI-1 
between HCPS and HFRS cases. Platelets, which are activated 
during blood clotting in the preparation of serum samples, 
are one of the major physiological sources of PAI-1 [8]. This 
affects baseline PAI-1 levels, as indicated by the increased con-
centration of PAI-1 in the serum of healthy volunteers (com-
pare Figure 1B and E). On the other hand, this effect is probably 
negligible in HCPS patient serum due to the often severe 
thrombocytopenia associated with the disease [9], and thus the 
difference between PAI-1 levels in HCPS patients and controls 
in circulation is most likely higher than estimated in this study. 
In fact, thrombocytopenia might explain the slightly lower 
level of PAI-1 in mild HCPS vs healthy controls (Figure  1B). 
Another potential caveat in our study is the fact that all se-
vere HCPS cases were, by definition, subjected to mechanical 
ventilation, which has the potential to increase the circulating 
levels of PAI-1 [10]. However, while we are not aware whether 
the analyzed samples were acquired before or after mechanical 
ventilation, we did not observe any changes in tPA or PAI-1 
levels in non-HCPS cases receiving similar treatment as com-
pared with HCPS cases (Figure  1A and B). Furthermore, by 
comparing fatal with nonfatal mechanically ventilated HCPS 
cases (Figure  1C), we observed a difference in PAI-1 levels, 
suggesting that ventilation per se is not a significant factor in 
the regulation of PAI-1 in HCPS. This is also in concordance 
with another study indicating that PAI-1 levels were increased 
in fatal vs nonfatal SNV-HCPS cases receiving mechanical ven-
tilation and/or extracorporeal membrane oxygenation [4]. All 
severe DOBV-HFRS cases received hemodialysis, which also 
potentially affects hemostasis [11]. However, all DOBV samples 
were acquired before hemodialysis, eliminating the influence of 
this factor in the observed results.
Taken together, it is possible that the observed increase in 
tPA/PAI-1 ratio accounts for elevated hemorrhagic compli-
cations and kidney failure in severe as compared with mild 
DOBV-HFRS. This is in line with our previous findings, where 
tPA, in the concurrent absence of neutralizing PAI-1, correlated 
with hemorrhages in PUUV-HFRS [7]. Analogously, the highly 
elevated levels of PAI-1 could also explain the absence of hem-
orrhages in severe HCPS [12], which is in striking contrast to 
severe HFRS cases [9]. Minor hemorrhages were reported in 
20% of our HCPS patients, but no correlations between bleed-
ing and disease severity, tPA, or PAI-1 were found (data not 
shown). Further studies on the role of tPA and PAI-1 in hanta-
virus diseases are certainly warranted.
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